MAP17 在结直肠癌中的表达是疾病复发的预后因素，即使在早期疾病阶段也预示着预后不良。

MAP17 Expression in Colorectal Cancer Is a Prognostic Factor for Disease Recurrence and Dismal Prognosis Already in Early Stage Disease.

机构信息

Clarunis, University Center for Gastrointestinal and Liver Disorders, Department of Visceral Surgery, University Hospital of Basel, Basel, Switzerland.

2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece.

出版信息

Oncology. 2021;99(7):471-482. doi: 10.1159/000515596. Epub 2021 Apr 14.

DOI:10.1159/000515596

PMID:33853080

Abstract

BACKGROUND

Disease recurrence in colorectal cancer constitutes a major cause of significant cancer-associated morbidity and mortality. MAP17 is a small protein, and its overexpression in malignant tumors has been correlated with aggressive tumor phenotypes. The aim of the present study was to investigate the expression patterns of MAP17 in colorectal cancer specimens and to assess its clinical significance.

PATIENTS AND METHODS

Surgical specimens of 111 patients with primary resectable colorectal cancer constituted the study population. Expression of MAP17 was assessed by immunohistochemistry, and the results were correlated with clinical and survival data.

RESULTS

MAP17 was expressed in cancer cells and endothelial cells of tumor blood vessels. Expression of MAP17 more than 10% was correlated with advanced disease stage (p < 0.001), higher T classification (p = 0.007), the presence of lymph node metastasis (p < 0.001), vascular (p = 0.013) and perineural invasion (p = 0.012). Patients exhibiting MAP17 expression of more than 30% in cancer cells compared to those expressing MAP17 less than 10% demonstrated a significantly worse 3-year progression-free survival (35.2 vs. 91%, p < 0.001) and 5-year overall survival (40.8 vs. 91%, p < 0.001). Cox regression analysis confirmed MAP17 expression of more than 30% as a prognostic marker of progression free survival (HR 0.136, 95% CI = 0.056-0.329, p < 0.001) and overall survival (HR 0.144 [95% CI) = 0.049-0.419, p < 0.001) independent of other clinicopathological characteristics. Statistically significantly worse 3-year progression-free survival and 5-year overall survival was demonstrated in the subgroup analysis of patients with early stage cancer only and high expression of MAP17.

CONCLUSIONS

High MAP17 expression in patients with colorectal cancer is a significant risk factor for cancer-associated morbidity and mortality already in early stage disease.

摘要

背景

结直肠癌的疾病复发是导致重大癌症相关发病率和死亡率的主要原因。MAP17 是一种小蛋白，其在恶性肿瘤中的过度表达与侵袭性肿瘤表型相关。本研究旨在探讨 MAP17 在结直肠癌标本中的表达模式，并评估其临床意义。

患者和方法

研究人群为 111 例原发性可切除结直肠癌患者的手术标本。通过免疫组织化学评估 MAP17 的表达，将结果与临床和生存数据相关联。

结果

MAP17 在癌细胞和肿瘤血管内皮细胞中表达。MAP17 表达超过 10%与疾病晚期（p < 0.001）、更高的 T 分类（p = 0.007）、淋巴结转移（p < 0.001）、血管（p = 0.013）和神经周围侵犯（p = 0.012）相关。与 MAP17 表达低于 10%的患者相比，MAP17 表达超过 30%的患者在癌症细胞中表现出显著更差的 3 年无进展生存（35.2% vs. 91%，p < 0.001）和 5 年总生存（40.8% vs. 91%，p < 0.001）。Cox 回归分析证实 MAP17 表达超过 30%是无进展生存的预后标志物（HR 0.136，95%CI = 0.056-0.329，p < 0.001）和总生存（HR 0.144 [95%CI] = 0.049-0.419，p < 0.001），独立于其他临床病理特征。仅在早期癌症患者和 MAP17 高表达的亚组分析中，MAP17 高表达与 3 年无进展生存和 5 年总生存的统计学显著恶化相关。